Table 2: Quality dimensions and items for guideline appraisal.
Quality dimensions / Item label |
AHA, 2018 |
Australia, 2016 |
Canada, 2017 |
HEARTs, 2018 |
ESC/ESH, 2018 |
Ethiopia, 2016 |
1. Information retrieval |
|
|
|
|
|
|
1.1. Health questions and outcomes |
√ |
√ |
√ |
√ |
√ |
√ |
1.2. Literature search |
√ |
√ |
√ |
√ |
√ |
X |
1.3. Literature selection |
√ |
√ |
√ |
√ |
√ |
X |
2. Evaluation of evidence |
|
|
|
|
|
|
2.1. Grading of evidence |
√ |
√ |
√ |
PA |
√ |
PA |
2.2. Consistency b/n evidence & recommendations |
√ |
√ |
√ |
PA |
√ |
PA |
3. Consideration of different perspectives |
|
|
|
|
|
|
3.1. Norms and values |
√ |
√ |
√ |
√ |
√ |
√ |
3.2. Expert knowledge |
√ |
√ |
√ |
√ |
√ |
√ |
3.3. Patient perspectives |
√ |
√ |
√ |
√ |
√ |
√ |
4. Formulation of recommendations |
|
|
|
|
|
|
4.1. Formulation of recommendations |
√ |
√ |
√ |
√ |
√ |
√ |
5. Transferability |
|
|
|
|
|
|
5.1. Comparability |
√ |
√ |
√ |
√ |
√ |
√ |
5.2. Costs |
√ |
√ |
√ |
√ |
√ |
√ |
5.3. Barriers and facilitators |
√ |
√ |
√ |
√ |
√ |
X |
6. Presentation of guideline content |
|
|
|
|
|
|
6.1. Benefits and harms |
√ |
√ |
√ |
√ |
√ |
√ |
6.2. Link to evidence |
√ |
√ |
√ |
√ |
√ |
X |
7. Alternatives |
|
|
|
|
|
|
7.1. Options for management |
√ |
√ |
√ |
√ |
√ |
√ |
7.2. Exceptions |
√ |
√ |
√ |
√ |
√ |
√ |
7.3. Patient preferences |
√ |
√ |
√ |
√ |
√ |
X |
8. Reliability |
|
|
|
|
|
|
8.1. Independent Review |
√ |
√ |
√ |
√ |
√ |
√ |
8.2. Pilot test |
√ |
√ |
√ |
√ |
√ |
X |
9. Scope |
|
|
|
|
|
|
9.1. Rationale and objective |
√ |
√ |
√ |
√ |
√ |
√ |
9.2. Guideline topic |
√ |
√ |
√ |
√ |
√ |
√ |
9.3. Practice setting |
√ |
√ |
√ |
√ |
√ |
√ |
9.4. Patient population |
√ |
√ |
√ |
√ |
√ |
X |
9.5. Provider population |
√ |
√ |
√ |
√ |
√ |
√ |
10. Independence |
√ |
√ |
√ |
√ |
√ |
√ |
10.1. Guideline development group |
√ |
√ |
√ |
√ |
√ |
√ |
10.2. Guideline development organization & funding |
√ |
√ |
√ |
√ |
√ |
√ |
10.3. Conflicts of interest |
√ |
√ |
√ |
√ |
√ |
√ |
11. Clarity and presentation |
|
|
|
|
|
|
11.1. Clarity |
√ |
√ |
√ |
√ |
√ |
√ |
11.2. Presentation |
√ |
√ |
√ |
√ |
√ |
√ |
12. Updating |
|
|
|
|
|
|
12. 1. Currentness |
√ |
√ |
√ |
√ |
√ |
X |
12.2. Scheduled review |
√ |
√ |
√ |
√ |
√ |
X |
13. Dissemination, Implementation, Evaluation |
|
|
|
|
|
|
13.1. Dissemination |
√ |
√ |
√ |
√ |
√ |
√ |
13.2. Implementation |
√ |
√ |
√ |
√ |
√ |
√ |
13.3. Evaluation |
√ |
√ |
√ |
√ |
√ |
X |
√: Yes; X: No; PA: Partially acceptable for guidelines that are copied from other guidelines.